Diabetes Stoffwechsel und Herz, published by VERLAG KIRCHHEIM, is a distinguished journal that focuses on the interdisciplinary field of diabetes research, cardiology, and metabolic disorders. With its dedicated approach, the journal aims to disseminate cutting-edge findings and foster innovative discussions among researchers and practitioners in the healthcare community. Despite its discontinuation in Scopus coverage since 2017, the journal continues to hold significance in advancing knowledge regarding the intricate relationship between diabetes and cardiovascular health. It offers researchers a platform to explore the biochemical, genetic, and clinical aspects of endocrinology, while also catering to the needs of professionals aiming to apply the latest research in their practice. The journal’s rankings, which place it in the lower percentiles across various relevant categories, reflect a unique opportunity for contributors looking to impact a niche yet vital area of medicine. As the field evolves, Diabetes Stoffwechsel und Herz remains committed to enriching the dialogue surrounding these critical health issues.

Diabetes Technology & Therapeutics is a leading journal published by MARY ANN LIEBERT, INC, dedicated to advancing the field of diabetes management through innovative technologies and therapeutic strategies. With an impressive impact factor and recognized as a Q1 journal in Endocrinology, Diabetes and Metabolism, as well as Medical Laboratory Technology, it occupies a pivotal position in the academic landscape. This esteemed publication features a comprehensive range of articles that cover cutting-edge research, clinical applications, and developments in diabetes care from 1999 to 2024, making it a critical resource for researchers, health professionals, and students alike. The journal is committed to fostering dialogue between disciplines, especially given its strong rankings in various scientific categories including the 98th percentile in Medical Laboratory Technology. By opting for subscription-based access, readers gain insight into the latest innovations that are shaping diabetes technology and treatment paradigms, thereby enhancing patient outcomes and advancing the scientific community's understanding of this complex disease.

DIABETES, published by the American Diabetes Association, is a premier journal in the field of endocrinology, diabetes, and metabolism, renowned for its rigorous peer-reviewed research since its inception in 1952. With an impressive impact factor and classified in the Q1 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine as of 2023, it holds a prestigious position within the scholarly community, ranked 17th out of 244 in its specialization. The journal's objective is to disseminate cutting-edge research and advance scientific understanding to ultimately improve diabetes patient care and management. While it does not offer open access options, the journal remains a vital resource for researchers, professionals, and students involved in diabetes-related studies. The ongoing dedication to excellence by the authors, reviewers, and editors ensures that DIABETES continues to be a pivotal platform for innovation and knowledge in the fight against diabetes.

Journal of Diabetes Investigation is a prestigious open-access journal published by WILEY, dedicated to advancing knowledge in the fields of Endocrinology, Diabetes, and Metabolism. With its ISSN 2040-1116 and E-ISSN 2040-1124, the journal provides a vital platform for researchers, healthcare professionals, and students to disseminate high-quality research, foster innovative ideas, and engage with cutting-edge developments in diabetes investigation. Since its inception in 2010, the journal has established a solid reputation, ranking in Q2 for Endocrinology and Diabetes and Metabolism, and Q1 for both Internal Medicine and Miscellaneous Medicine categories in 2023. Its Scopus rankings further underscore its impact, notably at the 76th percentile in Internal Medicine. The open access model, adopted in 2014, ensures that vital information is freely available, promoting global collaboration and knowledge sharing. The journal is not only a reflection of Australia's commitment to medical research but also a beacon for advancements that can ultimately enhance patient outcomes in diabetes care.

Diabetes Epidemiology and Management, published by Elsevier, is an innovative open-access journal that has been addressing the critical issues surrounding diabetes since its inception in 2021. This journal integrates a comprehensive exploration of the epidemiology, prevention, and management of diabetes, making it a pivotal resource within the fields of Endocrinology, Diabetes and Metabolism, and Internal Medicine. With a digital presence represented by E-ISSN 2666-9706, it currently holds a commendable position in the academic landscape, categorized in the Q3 quartile for both Endocrinology and Internal Medicine as per the 2023 metrics. The journal aims to enhance understanding and promote research on diabetes, offering authors a platform to share their findings with a global audience. Researchers, professionals, and students alike can benefit from this essential resource, which is dedicated to advancing the knowledge base and improving clinical practices in diabetes management. With open access options since 2021, the journal ensures that vital research is widely accessible, driving innovation and collaboration in the fight against diabetes.

The Journal of Diabetes and Metabolic Disorders, published by SPRINGER INT PUBL AG, is a premier academic journal dedicated to advancing research in the fields of endocrinology, diabetes, and metabolism. With an E-ISSN of 2251-6581, this journal plays a crucial role in disseminating high-quality research findings from 2012 to 2024, serving as a valuable resource for researchers, practitioners, and students alike. Notably, it has achieved impressive rankings, being placed in the Q2 quartile for Internal Medicine and Q3 for Endocrinology, Diabetes, and Metabolism in 2023, reflecting its influence within the scientific community. The Journal’s commitment to open access ensures that its comprehensive articles, encompassing topics from metabolic disorders to novel therapeutic approaches, are readily available to a global audience. Position yourself at the forefront of medical advancements—contribute to and benefit from the pivotal research presented in this journal.

DIABETES RESEARCH AND CLINICAL PRACTICE, published by Elsevier Ireland Ltd, is a leading peer-reviewed journal in the realms of endocrinology, diabetes, and internal medicine. With a prestigious Q1 classification across several categories, including Endocrinology, Diabetes and Metabolism, and Internal Medicine, this journal is recognized for its impactful contributions to advancing knowledge and clinical practice in diabetes care, boasting an impressive impact factor that underscores its significance in the academic community. Spanning from 1985 to 2024, this journal not only disseminates high-quality research but also serves as a critical resource for healthcare professionals, researchers, and students alike who are focused on addressing the global diabetes epidemic. With its comprehensive scope and commitment to fostering innovative findings, DIABETES RESEARCH AND CLINICAL PRACTICE remains at the forefront of its field, fostering collaboration and discovery to improve patient outcomes.

Diabetologie is a dedicated academic journal published by Springer Heidelberg, focusing on the diverse fields of endocrinology, diabetes, and metabolism. With the ISSN 2731-7447 and E-ISSN 2731-7455, this journal serves as a significant platform for the dissemination of innovative research and evidence-based practices within the rapidly evolving landscape of diabetes care and management. Although currently not classified as Open Access, the journal provides robust subscription options that grant access to a wealth of peer-reviewed articles, making it an invaluable resource for researchers and practitioners alike. With an H-index that reflects its emerging influence and a Scopus ranking in the 10th percentile within its category, Diabetologie aims to elevate the scientific understanding of diabetes through rigorous scholarship. The journal captures the latest findings and clinical advancements from 2022 to 2024, placing a particular emphasis on novel therapeutic strategies and technological innovations. By fostering a collaborative environment dedicated to the improvement of diabetes outcomes, Diabetologie stands as a crucial contributor to the global dialogue on diabetes treatment and research.

Diabetes Therapy is a prominent open access journal published by SPRINGER HEIDELBERG, dedicated to advancing our understanding of diabetes management and therapeutic strategies. Since its inception in 2010, the journal has provided a platform for high-quality research, showcasing innovative studies and clinical advances aimed at improving care for individuals with diabetes. With an established impact factor and categorized within the Q2 quartile in both Endocrinology, Diabetes and Metabolism and Internal Medicine in 2023, it ranks among the top journals in its field, reflecting its significant contribution to medical knowledge. Researchers, healthcare professionals, and students benefit from its comprehensive coverage of critical topics, ranging from pharmacological advancements to lifestyle interventions and cutting-edge technologies in diabetes management. With a Scopus rank placing it 35th in Internal Medicine, and 68th in Endocrinology, Diabetes, and Metabolism, Diabetes Therapy is recognized for its robust peer-reviewed content, making it an essential resource for anyone engaged in diabetes research and care.

Diabetology & Metabolic Syndrome is a premier open-access journal published by BMC, dedicated to advancing the field of endocrinology, diabetes, and metabolic syndrome. Since its inception in 2009, the journal has established itself as a leading platform for original research, reviews, and clinical studies, offering comprehensive insights into the complexities of metabolic diseases. With an impressive ranking in the 2023 category quartiles as Q1 in both Endocrinology, Diabetes and Metabolism, and Internal Medicine, it stands among the top-tier journals in its field. Researchers will appreciate its strong emphasis on disseminating critical findings that influence clinical practices and public health policies. Accessible to a global audience, Diabetology & Metabolic Syndrome's commitment to open access enables the distribution of high-quality research without barriers, fostering an inclusive environment for knowledge sharing. With a strategic focus on the intersection of diabetes management and metabolic disorders, this journal is essential for professionals seeking to stay abreast of the latest developments and contribute to a vital area of healthcare.